Impact of Body Mass Index on Safety and Efficacy of the Subcutaneous Implantable Cardioverter-Defibrillator.
This study determined whether obesity increased the risk of failed shocks and complications among subcutaneous implantable cardioverter-defibrillator (S-ICD) recipients. The S-ICD is an established treatment for patients at high risk for ventricular arrhythmias. Obesity may increase the transvenous defibrillation threshold and the rate of complications. We analyzed data from the 321 patients enrolled in the S-ICD Investigational Device Exemption (IDE) study. They were categorized into 3 body mass index (BMI) groups: <25 kg/m2 (underweight and normal), 25 to 30 kg/m2 (overweight), and >30 kg/m2 (obese). Patients underwent implantation followed by defibrillation testing at 65 J. Chronic defibrillation testing was repeated >150 days post implantation in a subset of patients. Seventy-nine patients had BMI <25 kg/m2, 105 had BMI 25 to 30 kg/m2, and 137 had BMI >30 kg/m2. A failed first shock of any kind occurred in 52 patients, including 41 patients during implant defibrillation testing, 11 patients during chronic defibrillation testing, and 5 patients during spontaneous ventricular arrhythmias. The rate of failed first shocks during implant defibrillation testing increased across BMI categories (5.1% among underweight and normal patients, 13.3% among overweight patients, and 16.9% among obese patients; p = 0.04). Among obese patients, shock impedance was higher during failed first shocks than successful first shocks (103.5 ohms vs. 84.6 ohms; p = 0.001). The rate of failed first shocks during chronic defibrillation testing and spontaneous ventricular arrhythmias did not significantly differ among BMI groups, nor did the rate of complications. Of the 8 underweight patients, there were no failed shocks or complications. Obese patients are at increased risk of failed first S-ICD shocks during defibrillation testing. Whether this can be overcome by optimal implantation techniques remains unknown. Rates of complications were not increased among obese patients.